Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.
about
Complete response of mediastinal clear cell sarcoma to pembrolizumab with radiotherapyPrimary Pulmonary Malignant Melanoma: Report of an Important Entity and Literature Review.A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity.Targeting the PD-1 pathway in pediatric solid tumors and brain tumors.[Malignant melanoma : Current status].Combination of DESI2 and IP10 gene therapy significantly improves therapeutic efficacy against murine carcinomaTreatment of Primary and Metastatic Multifocal Mucosal Melanoma of the Oral Cavity with ImatinibLy6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy.Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients.Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report.Melanoma subtypes demonstrate distinct PD-L1 expression profiles.Highlights of the season 2016–2017 by the Spanish Melanoma Group (GEM).Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab.The role of nivolumab in melanoma.Obstruction of BRAFV600E transcription by complementary PNA oligomers as a means to inhibit BRAF-mutant melanoma growth.Immunotherapy in managing metastatic melanoma: which treatment when?Immunotherapy in mucosal melanoma: a case report and review of the literature.Itraconazole treatment of primary malignant melanoma of the vagina evaluated using positron emission tomography and tissue cDNA microarray: a case report.Anti-PD-1 monotherapy versus anti-PD1 plus anti-CTLA4 in advanced melanoma: how do we decide?What is new in melanoma after European Cancer Congress 2017?Are checkpoint inhibitors a valuable option for metastatic or unresectable vulvar and vaginal melanomas?Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in TaiwanPrognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New EvidencesPredominance of triple wild-type and IGF2R mutations in mucosal melanomasCombatting mucosal melanoma: recent advances and future perspectives
P2860
Q33910525-DE377F08-2E68-4896-B2D3-04D97C585E04Q37703415-60EEB77A-9FC5-4AAD-9E13-9CD7660A06C4Q38713958-B26E3B01-28F5-4A54-BDE0-01ED84113F8EQ38819982-9E7B0978-B414-4AC6-9DE3-88E5CFA40A6CQ40113867-D52086E7-B1F9-4131-8FEF-E48565902E4AQ41347031-38D7906F-94A4-4540-AAC4-040C2AA0CAEFQ41488462-33138D81-D34E-4B72-BB09-3DA473768D5DQ42644178-83F61805-9D93-4580-9903-4F934F98CE65Q43110773-14C2D69F-8A4C-49DF-B19D-77B3C268E683Q47096567-CB8ECA5A-7531-4160-ACFF-6E9450B1A579Q47107364-62CD5889-F085-47DC-AD46-1E7E6E26F7DFQ47217258-2BEFD807-1AE2-4B53-82EE-7AE2CFCA9046Q47688850-444715DE-9730-4ECA-B00F-F139B4483F94Q47735641-5A1BCC25-4D20-4741-8EE3-550A96F45AB0Q47762933-CFAF4DE1-C5CE-4E13-9E99-40CF43B17F4BQ50166276-A356A36E-1889-43F7-9BA3-BF17FCEE166DQ55053720-96473FBC-5F2C-4186-AC25-427FE60A8AFAQ55489012-BEF6BEED-4DC2-4B38-871F-62E8DC2C65D0Q56893675-51EC363F-6841-4263-822F-641EDEC5882DQ56894089-BD512BF2-84CF-427D-A805-77C28CF81481Q57166568-6B9A6286-8CA4-4D35-98B1-71AAC5B32D39Q57167691-C5EC585E-E76C-488D-9371-AE80828CC6C5Q57191808-4C652D5F-C0B1-4570-880E-17BAAF3E7446Q58093307-8DF298A2-4AA8-4BBA-9921-62EECAC511B5Q59126427-66A0C144-1387-4DC1-B251-6245AE1828B1
P2860
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Efficacy and Safety of Nivolum ...... l Melanoma: A Pooled Analysis.
@en
Efficacy and Safety of Nivolum ...... l Melanoma: A Pooled Analysis.
@nl
type
label
Efficacy and Safety of Nivolum ...... l Melanoma: A Pooled Analysis.
@en
Efficacy and Safety of Nivolum ...... l Melanoma: A Pooled Analysis.
@nl
prefLabel
Efficacy and Safety of Nivolum ...... l Melanoma: A Pooled Analysis.
@en
Efficacy and Safety of Nivolum ...... l Melanoma: A Pooled Analysis.
@nl
P2093
P2860
P356
P1476
Efficacy and Safety of Nivolum ...... l Melanoma: A Pooled Analysis.
@en
P2093
Alexander N Shoushtari
Bart Neyns
Benjamin Brady
Celeste Lebbé
F Stephen Hodi
Henrik Schmidt
Ivan Marquez-Rodas
James Larkin
Jedd D Wolchok
Jeffrey A Sosman
P2860
P304
P356
10.1200/JCO.2016.67.9258
P407
P577
2016-11-07T00:00:00Z